A review of current strategies for treatment resistant obsessive-compulsive disorder

Current Drug Therapy

Volumn 3, Issue 2, 2008, Pages 126-142

  Maina, Giuseppe ^a   Albert, Umberto ^a   Salvi, Virginio ^a   Bogetto, Flippo ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Antipsychotic augmentation; Obsessive compulsive disorder; Resistance; Switch

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CITALOPRAM; CLOMIPRAMINE; CLONAZEPAM; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; LITHIUM SALT; LORAZEPAM; MIRTAZAPINE; MORPHINE; NEUROLEPTIC AGENT; OLANZAPINE; OPIATE DERIVATIVE; PAROXETINE; PIMOZIDE; PINDOLOL; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THIORIDAZINE; TIOTIXENE; UNINDEXED DRUG; VENLAFAXINE;

ADD ON THERAPY; BRAIN DEPTH STIMULATION; CAPSULOTOMY; CLINICAL TRIAL; COGNITIVE THERAPY; DIABETES MELLITUS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSTONIA; ELECTROCONVULSIVE THERAPY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; LETHARGY; LONG TERM CARE; METABOLIC DISORDER; MONOTHERAPY; NEUROSURGERY; OBSESSIVE COMPULSIVE DISORDER; PALLIDOTOMY; PRIORITY JOURNAL; PSYCHOTHERAPY; QUALITY OF LIFE; REVIEW; TARDIVE DYSKINESIA; TREATMENT RESPONSE;

EID: 54949149617     PISSN: 15748855     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488508784221235     Document Type: Review

References (197)

1. Sasson Y, Zohar J, Chopra M, et al. Epidemiology of obsessive-compulsive disorder: a world view. J Clin Psychiatry 1997; 58(suppl 12): 7-10.
2. CordobaE, Lopez-IborJJ. La monochlorimipramina en enfermes psiqiutricos resistantes on atros tratamientes. Actas Luso Esp Neurol Psiquiatr 1967; 26: 119.
3. Meyer V. Modification of expectations in cases with obsessional rituals. Behav Res Ther 1966; 4: 273-80.
4. Marks IM, Hodgson R, Rachman S. Treatment of chronic obsessive-compulsive neurosis by in-vivo exposure. A two-year follow-up and issues in treatment. Br J Psychiatry 1975; 127: 349-64.
5. March J, Frances A, Carpenter D, Kahn D, eds. The Expert Consensus Guideline Series. Treatment of obsessive-compulsive disorder. J Clin Psychiatry 1997; 58(suppl 4): 2-72.
6. Bandelow B, Zohar J, Hollander E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders. World J Biol Psychiatry 2002; 3: 171-199.
7. Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2005; 19: 567-596.
8. Canadian Psychiatric Association. Clinical practice guidelines. Management of anxiety disorders. Can J Psychiatry 2006; 51(8 Suppl 2): 9S-91S.
9. APA 2007
10. Thoren P, Asberg M, Cronholm B, Jornestedt L, Traskman L. Clomipramine treatment of obsessive-compulsive disorder. I. A controlled clinical trial. Arch Gen Psychiatry 1980; 37: 1281-1285.
11. Mavissakalian M, Turner SM, Michelson L, Jacob R. Tricyclic antidepressants in obsessive-compulsive disorder: antiobsessional or antidepressant agents? II. Am J Psychiatry 1985; 142: 572-6.
12. Jenike MA, Baer L, Summergrad P, Weilburg JB, Holland A, Seymour R. Obsessive-compulsive disorder: a double-blind, placebo-controlled trial of clomipramine in 27 patients. Am J Psychiatry 1989; 146: 1328-1330.
13. Greist JH, Jefferson JW, Rosenfeld R. Gutzmann LD, March JS, Barlage NE. Clomipramine and obsessive compulsive disorder: a placebo-controlled double-blind study of 32 patients. J Clin Psychiatry 1990; 51: 292-297.
14. Montgomery SA, Montgomery DB, Fineberg N. Early response with clomipramine in obsessive-compulsive disorder-a placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry 1990; 14: 719-727.
15. Mavissakalian MR, Jones B, Olson B, Perel JM. Clomipramine in obsessive-compulsive disorder: clinical response and plasma levels. Clin Psychopharmacol 1990; 10: 261-268.
16. Clomipramine in the treatment of patients with obsessive compulsive disorder. The clomipramine collaborative study group. Arch Gen Psychiatry 1991; 48: 730-738.
17. Perse TL, Greist JH, Jefferson JW, Rosenfeld R, Dar R. Fluvoxamine treatment of obsessive-compulsive disorder. Am J Psychiatry 1987; 144: 1543-1548.
18. Goodman WK, Price LH, Rasmussen SA, Delgado PL, Heninger GR, Charney DS. Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo. Arch Gen Psychiatry 1989; 46: 36-44.
19. Jenike MA, Hyman S, Baer L, et al. A controlled trial of fluvoxamine in obsessive-compulsive disorder: implications for a serotonergic theory. Am J Psychiatry 1990; 147: 1209-15.
20. Goodman WK, Kozak MJ, Liebowitz M, et al. Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial. Int Clin Psychopharmacol 1996; 11: 21-29.
21. Hollander E, Koran LM, Goodman WK, et al. A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder. J Clin Psychiatry 2003; 64: 640-7
22. Montgomery SA, McIntyre A, Osterheider M, et al. A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. The Lilly European OCD Study Group. Eur Neuropsychopharmacol 1993; 3(2): 143-152.
23. Tollefson G, Rampey A, Potvin J, et al. A multi-center investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 1994; 51: 559-67.
24. Romano S, Goodman W, Tamura R, Gonzalez J, The Collaborative Research Group. Long-term treatment of obsessive-compulsive disorder after an acute response: a comparison of fluoxetine versus placebo. J Clin Psychopharmacol 2001; 21: 46-52.
25. Zohar J, Judge R. Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. Br J Psychiatry 1996; 169: 468-474.
26. Hollander E, Allen A, Steiner M, Wheadon DE, Oakes R, Bunnham DB. Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine. J Clin Psychiatry 2003; 64: 1113-1121.
27. Kamijima K, Murasaki M, Asai M, et al. Paroxetine in the treatment of obsessive-compulsive disorder: randomized, double-blind, placebo-controlled study in Japanese patients. Psychiatry Clin Neurosci 2004; 58: 427-33.
28. Chouinard G, Goodman W, Greist J, et al. Results of a double-blind placebo-controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder. Psychopharmacol Bull 1990; 26: 279-84.
29. Greist HJ, Chouinard G, DuBoff E, et al. Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch Gen Psychiatry 1995; 52: 289-95.
30. Kronig MH, Apter J, Asnis G, et al. Placebo-controlled, multicenter study of sertraline treatment for obsessive-compulsive disorder. J Clin Psychopharmacol 1999; 19: 172-6.
31. Montgomery SA, Kasper S, Stein DJ, Bang Hedergaard K, Lemming OM. Citalopram 20 mg, 40 mg, and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder. Int Clin Psychopharmacol 2001; 16(2): 75-86.
32. Stein DJ, Andersen EW, Tonnoir B, Fineberg N. Escitalopram in obsessive-compulsive disorder: a randomized, placebo-controlled, panoxetine-referenced, fixed-dose, 24-week study. Curr Med Res Opin 2007; 23(4): 701-11.
33. Albert U, Maina G, Aguglia E, Bogetto F. Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary single-blind, 12-week, controlled study. J Clin Psychiatry 2002; 63: 1004-9.
34. Denys D, Van Der Wee N, Van Megen HJ, Westenberg HG. A double-blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder. J Clin Psychopharmacol 2003; 23: 568-75.
35. Fineberg NA, Gale TM. Evidence-based pharmacotherapy of obsessive-compulsive disorder. Int J Neuropsychopharmacol 2005; 8: 107-129.
36. Heyman I, Mataix-Cols D, Fineberg NA. Obsessive-compulsive disorder. BMJ 2006; 333(7565): 424-9.
37. Fontenelle LF, Nascimento AL, Mendlowicz MV, Shavitt RG, Versiani M. An update on the pharmacological treatment of obsessive-compulsive disorder. Expert Opin Pharmacother 2007; 8(5): 563-83.
38. van Balkom AJ, de Haan E, van Oppen P, Spinhoven P, Hoogdui K.A, van Dyck R. Cognitive and behavioral therapies alone versus in combination with fluvoxamine in the treatment of obsessive compulsive disorder. J Nerv Ment Dis 1998; 186(8): 492-9.
39. Kobak KA, Greist JH, Jefferson JW, et al. Behavioral versus pharmacological treatments of obsessive-compulsive disorder: a meta-analysis. Psychopharmacology 1998; 136: 205-16.
40. Eddy KT, Dutra L, Bradley R, Westen D. A multidimensional meta-analysis of psychotherapy and pharmacotherapy for obsessive-compulsive disorder. Clin Psychol Rev 2004; 24: 1011-3.
41. Simpson HB, Liebowitz MR, Foa EB, et al. Post-treatment effects of exposure therapy and clomipramine in obsessive-compulsive disorder. Depress Anxiety 2004; 19(4): 225-33.
42. Pallanti S, Hollander E, Bienstock C, et al. Treatment non-response in OCD: methodological issues and operational definitions. Int J Neuropsychopharmacol 2002; 5(2): 181-91.
43. Rauch SL, Jenike MA. Management of treatment-resistant obsessive-compulsive disorder: concepts and strategies. In: Hollander E, Zohar J, Marazziti D, Olivier B, eds. Current insights in obsessive-compulsive disorder. Chichester: John Wiley & Sons Ltd. 1994.
44. Pallanti S, Quercioli L. Treatment-refractory obsessive-compulsive disorder: methodological issues, operational definitions and therapeutic lines. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 400-12.
45. De Haan E, van Oppen P, van Balkom AJ, et al. Prediction of outcome and early vs. late improvement in OCD patients treated with cognitive behaviour therapy and pharmacotherapy. Acta Psychiatr Scand 1997; 96: 354-61.
46. McDonough M, Kennedy N. Pharmacological management of obsessive-compulsive disorder: a review for clinicians. Harv Rev Psychiatry 2002; 10(3): 127-37.
47. Zohar J, Sasson Y, Chopra M, et al. Pharmacological treatment of obsessive-compulsive disorder: a review, In: Maj M, Sartorius N, Okasha O, Zohar J (Eds.). Obsessive-compulsive disorder. London, John Wiley and Sons, 2000; 43-61.
48. Koran LM, Pallanti S, Paiva RS, Quercioli L. Pulse loading versus gradual dosing of intravenous clomipramine in obsessive-compulsive disorder. Eur Neuropsychopharmacol 1998; 8(2): 121-6.
49. Bogetto F, Albert U, Maina G. Sertraline treatment of obsessive-compulsive disorder: efficacy and tolerability of a rapid titration regimen. Eur Neuropsychopharmacol 2002; 12: 181-6.
50. Pallanti S, Quercioli L, Bruscoli M. Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study. J Clin Psychiatry 2004; 65: 1394-9.
51. Albert U, Salvi V, Saracco P, Bogetto F, Maina G. Health-related quality of life among first degree relatives of patients with obsessive-compulsive disorder in Italy. Psychiatr Serv 2007; 58(7): 970-6.
52. Van Noppen B, Steketee G. Family responses and multifamily behavioral treatment for obsessive-compulsive disorder. Brief Treat Crisis Interv 2003; 3: 231-47.
53. Van Noppen B, Steketee G, Pato M. Group and multifamily behavioral treatments for OCD. In: Hollander E, Stein D. (Eds.). Obsessive-compulsive disorder: diagnosis, etiology, treatment. New York: Marcel Dekker 1997; 331-66.
54. Albert U, Maina G, Saracco P, Bogetto F. Multifamily Psychoeducational Intervention (MPI) for obsessive-compulsive study: a pilot study. Epidemiologia e Psichiatria Sociale 2006; 15(1): 70-5.
55. Maina G, Saracco P, Albert U. Family-focused treatments for obsessive-compulsive disorder. Clin Neuropsychiatry 2006; 3(6): 382-90.
56. Simpson HB, Gorfinkle KS, Liebowitz MR. Cognitive-behavioral therapy as an adjunct to serotonin reuptake inhibitors in obsessive-compulsive disorder: an open trial. J Clin Psychiatry 1999; 60(9): 584-90.
57. Kampman M, Keijsers GPJ, Hoogduin CAL, Verbraak MJPM. Addition of cognitive-behavior therapy for obsessive-compulsive disorder patients non-responding to fluoxetine. Acta Psychiatr Scand 2002; 106: 314-9.
58. Albert U, Maina G, Forner F, Bogetto F. Cognitive-behavioral therapy in obsessive-compulsive disorder patients partially unresponsive to SRIs. Eur Neuropsychopharmacol 2003; 13(suppl 4): S357.
59. Tolin DF, Maltby N, Diefenbach GJ, Hannan SE, Worhunsky P. Cognitive-behavioural therapy for medication nonresponders with obsessive-compulsive disorder: a wait-list-controlled open trial. J Clin Psychiatry 2004; 65: 922-31.
60. McDougle CJ, Goodman WK, Price LH, et al. Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder. Am J Psychiatry 1990; 147: 652-4.
61. McDougle, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind placebo-controlled study in patients with and without tics. Arch Gen Psychiatry 1994; 51: 302-8.
62. Jacobsen FM. Risperidone in the treatment of affective illness and obsessive-compulsive disorder. J Chin Psychiatry 1995; 56: 423-9.
63. McDougle CJ, Fleischman RL, Epperson CN, et al. Risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases. J Clin Psychiatry 1995; 56: 526-8.
64. Ravizza L, Barzega G, Bellino S, Bogetto F, Maina G. Therapeutic effect and safety of adjunctive risperidone in refractory obsessive-compulsive disorder (OCD). Psychopharmacol Bull 1996; 32(4): 677-82.
65. Saxena S, Wang D, Bystritsky A, Baxter LR Jr. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. J Clin Psychiatry 1996; 57: 303-6.
66. Stein DJ, Bouwer C, Hawkridge S, Emsley RA. Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders. J Clin Psychiatry 1997; 58: 119-22.
67. Salmeron JM, Alcantara AG, Barcia D. Combination of risperidone and serotonergic antidepressant in refractory obsessive-compulsive disorder. Actas Luso Esp Neurol Psiquiatr Cienc Afines 1998; 26(6): 399-402.
68. Kawahara T, Ueda Y, Mitsuyama Y. A case report of refractory obsessive-compulsive disorder improved by risperidone augmentation of clomipramine treatment. Psychiatry Clin Neurosci 2000; 54(5): 599-601.
69. Pfanner C, Marazziti D, Dell'Osso L, et al. Risperidone augmentation in refractory obsessive-compulsive dirorder: an open-label study. Int Clin Psychopharmacol 2000; 15: 297-301.
70. Sun TF, Lin PY, Wu CK. Risperidone augmentation of specific serotonin reuptake inhibitors in the treatment of refractory obsessive-compulsive disorder: report of two cases. Chang Gung Med J 2001; 24: 587-92.
71. Yoshimura R, Kaneko S, Shinkai K, Nakamura J. Successful treatment for obsessive-compulsive disorder with addition of low-dose risperidone to fluvoxamine: implications for plasma levels of catecholamine metabolites and serum brain-derived neurotrophic factor levels. Psychiatry Clin Neurosci 2006; 60(3): 389-93.
72. Arias Horcajadas F, Soto JA, Garcia-Cantalapiedra MJ, Rodriguez Calvin JL, Morales J, Salgado M. Effectiveness and tolerability of addition of risperidone in obsessive-compulsive disorder with poor response to serotonin reuptake inhibitors. Actas Esp Psiquiatr 2006; 34(3): 147-52.
73. Fitzgerald KD, Stewart CM, Tawile V, Rosenberg DR. Risperidone augmentation of serotonin reuptake inhibitor treatment of pediatric obsessive compulsive disorder. J Child Adolesc Psychopharmacol 1999; 9(2): 115-23.
74. Thomsen PH. Risperidone augmentation in the treatment of severe adolescent OCD in SSRI-refractory cases: a case-series. Ann Clin Psychiatry 2004; 16(4): 201-7.
75. McDougle CJ, Epperson CN, Pelton GH, et al. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 2000; 57: 794-801.
76. Hollander E, Rossi NB, Sood E, Pallanti S. Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. Int J Neuropsychopharmacol 2003; 6(4): 397-401.
77. Erzegovesi S, Guglielmo E, Siliprandi F, Bellodi L. Low-dose augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study. Eur Neuropsychopharmacol 2005; 15: 69-74.
78. Li X, May RS, Tolbert LC, Jackson WT, Flournoy JM, Baxter LR. Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study. J Clin Psychiatry 2005; 66(6): 736-43.
79. Potenza MN, Wasylink S, Longhurst JG, et al. Olanzapine augmentation of fluoxetine in the treatment of refractory obsessive-compulsive disorder. J Clin Psychopharmacol 1998; 18(5): 423-4.
80. Marazziti D, Pallanti S. Effectiveness of olanzapine treatment for severe obsessive-compulsive disorder. Am J Psychiatry 1999; 156(11): 1834-5.
81. Weiss EL, Potenza MN, McDougle CJ, Epperson CN. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series. J Clin Psychiatry 1999; 60: 524-7.
82. Bogetto F, Bellino S, Vaschetto P, Ziero S. Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial. Psychiatr Res 2000; 96: 91-8.
83. Koran LM, Ringold AL, Elliott MA. Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 2000; 61: 514-7.
84. Marusic A, Farmer A. Antidepressant augmentation with low-dose olanzapine in obsessive-compulsive disorder. Br J Psychiatry 2000; 177: 567.
85. Francobandiera G. Olanzapine augmentation of serotonin uptake inhibitors in obsessive-compulsive disorder: an open study. Can J Psychiatry 2001; 46(4): 356-8.
86. Crocq MA, Leclercq P, Guillon MS, Bailey PE. Open-label olanzapine in obsessive-compulsive disorder refractory to antidepressant treatment. Eur Psychiatry 2002; 63(11): 1046-7.
87. D'Amico G, Cedro C, Muscatello MR, et al. Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder. Porg Neuropsychopharmacol Biol Psychiatry 2003; 27(4): 619-23.
88. Bystritsky A, Ackerman DL, Rosen RM, et al. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial. J Clin Psychiatry 2004; 65: 565-8.
89. Shapira NA, Ward HE, Mandoki M, et al. A double blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder. Biol Psichiatry 2004; 550: 553-5.
90. Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry 2006; 11: 622-32.
91. Denys D, Van Megen H, Westenberg HGM. Quetiapine addition to serotonin reuptake inhibitor treatment in patients with treatment-refractory obsessive-compulsive disorder: an open-label study. J Clin Psychiatry 2002; 63(8): 700-3.
92. Mohr N, Vythilingum B, Emsey RA, Stein DJ. Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder. Int Clin Psychopharmacol 2002; 17: 37-40.
93. Francobandiera G. Quetiapine augmentation of sertraline in obsessive-compulsive disorder. J Clin Psychiatry 2002; 63(11): 1046-7.
94. Sevincok L, Topuz A. Lack of efficacy of low doses of quetiapine addition in refractory obsessive-compulsive disorder. J Clin Psychopharmacol 2003; 23(5): 448-50.
95. Misri S, Milis L. Obsessive-compulsive disorder in the postpartum. Open label trial of quetiapine augmentation. J Clin Psychopharmacol 2004; 24: 624-7.
96. Bogan AM, Koran LM, Chuong HW, Vapnik T, Bystristky A. Quetiapine augmentation in obsessive-compulsive disorder resistant to serotonin reuptake inhibitors: an open-label study. J Clin Psychiatry 2005; 66: 73-9.
97. Dell'Osso B, Mundo E, Altamura AC. Quetiapine augmentation of selective serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a six-month follow-up case series. CNS Spectr 2006; 11(11): 879-83.
98. Atmaca M, Kuloglu M, Tezcan E, Gecici O. Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study. Int Clin Psychopharmacol 2002; 17: 115-9.
99. Denys D, De Geus F, Van Megen HJ, Westenberg HG. doubleblind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin re-uptake inhibitors. J Clin Psychiatry 2004; 65: 1040-8.
100. Fineberg NA, Sivakumaran T, Roberts A, Gale T. Adding quetiapine to SRI in treatment-resistant obsessive-compulsive disorder: a randomized controlled treatment study. Int Clin Psychopharmacol 2005; 20: 223-6.
101. Carey PD, Vythilingum B, Seedat S, et al. Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study. BMC Psychiatry 2005; 5(1): 5.
102. Fineberg NA, Stein DJ, Premukar P, et al. Adjunctive quetiapine for serotonin re-uptake inhibitor-resistant obsessive-compulsive disorder: a meta-analysis of randomized controlled treatment trials. Int Clin Psychopharmacol 2006; 21: 337-43.
103. Metin O, Yazici K, Tot S, Yazici AE. Amisulpiride augmentation in treatment resistant obsessive-compulsive disorder: an open trial. Hum Psychopharmacol 2003; 18(6): 463-7.
104. Connor KM, Payne VM, Gadde KM, Zhang W, Davidson JR. The use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients. J Clin Psychiatry 2005; 66: 49-51.
105. Skapinakis P, Papatheodorou T, Mavreas V. Antipsychotic augmentation of serotonergic antidepressants in treatment-resistant obsessive-compulsive disorder: a meta-analysis of the randomized controlled trials. Eur Neuropsychopharmacol 2007; 17: 79-93.
106. Maina G, Albert U, Ziero S, Bogetto F. Antipsychotic augmentation for treatment-resistant obsessive-compulsive disorder: what if antipsychotic is discontinued? Int Clin Paychopharmacol 2003; 18: 23-28.
107. Simeon JG, Thatte S, Wiggins D. Treatment of adolescent obsessive-compulsive disorder with a clomipramine-fluoxetine combination. Psychopharmacol Bull 1990; 26(3): 285-90.
108. Browne M, Horn E, Jones TT. The benefits of clomipramine-fluoxetine combination in obsessive compulsive disorder. Can J Psychiatry 1993; 38: 242-3.
109. Ravizza L, Barzega G, Bellino S, Bogetto F, Maina G. Drug treatment of obsessive-compulsive disorder (OCD): long-term trial with clomipramine and selective serotonin reuptake inhibitors (SSRIs). Psychopharmacol Bull 1996; 32(1): 167-73.
110. Figueroa Y, Rosenberg DR, Birmaher B, Keshavan MS. Combination treatment with clomipramine and selective serotonin reuptake inhibitors for obsessive-compulsive disorder in children and adolescents. J Child Adolesc Psychopharmacol 1998; 8(1): 61-7.
111. Pallanti S, Quercioli L, Paiva RS, Koran LM. Citalopram for treatment-resistant obsessive-compulsive disorder. Eur Psychiatry 1999; 14(2): 101-6.
112. McDougle CJ, Price LH, Goodman WK. A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy. J Clin Psychopharmacol 1991; 11: 175-84.
113. Pigott TA, L'Heureux F, Hill JL, et al. A controlled comparison of adjunctive lithium carbonate or thyroid hormone in clomipramine-treated patients with obsessive-compulsive disorder. J Clin Psychopharmacol 1991; 11: 242-248.
114. Pigott TA, L'Heureux F, Hill JL, et al. A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorder. J Clin Psychopharmacol 1992; 12: 11-8.
115. Grady TA, Pigott TA, L'Heureux F, et al. Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder. Am J Psychiatry 1993; 150: 818-21.
116. McDougle, Goodman WK, Leckman JF, et al. Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder. Am J Psychiatry 1993; 150: 647-649.
117. Moroz G. High-potency benzodiazepines: recent clinical results. J Clin Psychiatry 2004; 65(Suppl 5): 13-8.
118. Pigott TA, L'Heureux F, Rubenstein CS, Hill JL, Murphy DL. A controlled trial of clonazepam augmentation in OCD patients treated with clomipramine or fluoxetine. In: New Research Program and Abstracts of the 145th Annual Meeting of the American Psychiatric Association. Washington, DC: American Psychiatric Association, 1992: 82 (Abstract NR 144).
119. Crockett BA, Churchill E, Davidson JR. A double-blind combination study of clonazepam with sertraline in obsessive-compulsive disorder. Ann Clin Psychiatry 2004; 16(3): 127-32.
120. Blier P, Bergeron R. Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J Clin Psychopharmacol 1996; 15(3): 217-22.
121. Bakish D, Hooper CL, Thornton MD, Wiens A, Miller CA, Thibaudeau CA. Rapid onset: an open study of the treatment of major depressive disorder with nefazodone and pindolol combination therapy. Int Clin Psychopharmacol 1997; 12(2): 91-97.
122. Blier P, Bergeron R. The use of pindolol to potentiate antidepressant medication. J Clin Psychiatry 1998; 59: 16-23.
123. Bordet R, Thomas P, Dupuis B. Effect of pindolol on onset of action of paroxetine in the treatment of major depression: intermediate analysis of a double-blind, placebo-controlled trial. Reseau de Recherche et d'Experimentation Psychopharmacologique. Am J Psychiatry 1998; 155: 1346-51.
124. Mundo E, Guglielmo E, Bellodi L. Effect of adjuvant pindolol on the antiobsessional response to fluvoxamine: a double-blind placebo-controlled study. Int Clin Psychopharmacol 1998; 13: 219-224.
125. Dannon PN, Sasson Y, Hirschmann S, Iancu I, Grunhaus LJ, Zohar J. Pindolol augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind placebo controlled trial. Eur Neuropsychopharmacol 2000; 10: 165-9.
126. Warneke L. A possible new treatment approach to obsessive-compulsive disorder. Can J Psychiatry 1997; 42(6): 667-8.
127. Shapira NA, Keck PE Jr, Goldsmith TD, McConville BJ, Eis M, McElroy SL. Open-label pilot study of tramadol hydrochloride in treatment-refractory obsessive-compulsive disorder. Depress Anxiety 1997; 6(4): 170-3.
128. Koran LM, Aboujaoude E, Bullock KD, Franz B, Gamel N, Elliott M. Double-blind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 2005; 66: 353-9.
129. Seedat S, Stein DJ. Inositol augmentation of serotonin reuptake inhibitors in treatment-refractory obsessive-compulsive disorder: an open trial, Int Clin Psychopharmacol 1999; 14(6): 353-6.
130. Fux M, Benjamin J, Belmaker RH. Inositol versus placebo augmentation of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: a double-blind, cross-over study. Int J Psychopharmacol 1999; 2(3): 193-195.
131. Hollander E, Fay M, Liebowitz MR. Clonidine and clomipramine in obsessive-compulsive disorder. Am J Psychiatry 1988; 145: 388-389.
132. Cora-Locatelli G, Greenberg BD, Martin J, Murphy DL. Gabapentin augmentation for fluoxetine-treated patients with obsessive-compulsive disorder. J Clin Psychiatry 1998; 59: 480-481.
133. Coric V, Taskiran S, Pittenger C, et al. Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol Psychiatry 2005; 58(5): 424-8.
134. Van Ameringen M, Mancuni C, Patterson B, Bennett M. Topiramate augmentation in treatment-resistant obsessive-compulsive disorder: a retrospective, open-label case series. Depress Anxiety 2006; 23(1): 1-5.
135. Greist JH, Jefferson JW. Pharmacotherapy for obsessive-compulsive disorder. Br J Psychiatry 1998; 173(suppl 35): 64-70.
136. Reardon JP, Amsterdam JD. Overview of treatment-resistant depression and its management In: Amsterdam JD, Hornig M, Nieremberg AA. Treatment-resistant mood disorders. Cambridge University Press, Cambridge, UK, 2001; 30-45.
137. Warneke LB. Intravenous chlorimipramine therapy in obsessive-compulsive disorder. Can J Psychiatry 1989; 34: 853-9.
138. Fallon BA, Campeas R, Schneier FR, et al. Open trial of intravenous clomipramine in five treatment-refractory patients with obsessive-compulsive disorder. J Neuropsychiatry Clin Neurosci 1992; 4(1): 70-5.
139. Fallon BA, Liebowitz MR, Campeas R, et al. Intravenous clomipramine for obsessive-compulsive disorder refractory to oral clomipramine. Arch Gen Psychiatry 1998; 55: 918-24.
140. Koran LM, Sallee FR, Pallanti S, et al. Intravenous pulse loading of clomipramine producec rapid benefit in obsessive-compulsive disorder. Am J Psychiatry 1997; 154: 396-401.
141. Koran LM, Aboujaoude E, Ward H, et al. Pulse-loaded intravenous clomipramine in treatment-resistant obsessive-compulsive disorder. J Clin Psychopharmacol 2006; 26: 79-83.
142. Pallanti S, Quercioli L, Koran LM. Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial. J Clin Psychiatry 2002; 63(9): 796-801.
143. Ackerman DL, Greenland S, Bystritsky A. Clinical characteristics of response to fluoxetine treatment of obsessive-compulsive disorder. J Clin Psychopharmacol 1998; 18(3): 185-92.
144. Rasmussen SA, Eisen LJ, Paro MT. Current issues in the pharmacologic management of obsessive-compulsive disorder. J Clin Psychiatry 1993; 54(suppl): 4-9.
145. Goodman WK, Ward H, Kablinger A, Murphy T. Fluvoxamine in the treatment of obsessive-compulsive disorder and related conditions. J Clin Psychiatry 1997; 58(Suppl 5): 32-49.
146. Marazziti D, Dell'Osso L, Gemignani A, et al. Citalopram in refractory obsessive-compulsive disorder: an open study. Int Clin Psychopharmacol 2001; 16: 215-219.
147. Jenike MA. Drug treatment of obsessive-compulsive disorder. In: Jenike MA, Baer L, Munichiello WE, eds. Obsessive-compulsive disorders: theory and management. Chicago: Year Book Medical Publishing. 1990; 249-82.
148. Greist HJ. An integrated approach to treatment of obsessive-compulsive disorder. J Clin Psychiatry 1992; 53(suppl 4): 38-41.
149. Goodman WK, McDougle CJ, Barr LC, et al. Biological approaches to the treatment resistant obsessive-compulsive disorder. J Clin Psychiatry 1993; 54(suppl 6): 16-26.
150. Zohar J, Ayuso-Gutierrez JL, D'Haenen H, et al. Treatment of obsessive-compulsive disorder: algorithms for pharmacotherapy. Int J Psych Clin Pract 1997; 1(suppl 1): 17-23.
151. Albert U, Bergesio C, Pessina E, Maina G, Bogetto F. Management of treatment resistant obsessive-compulsive disorder: algorithms for pharmacotherapy. Panminerva Med 2002; 44(2): 83-91.
152. Pigott TA, Pato MT, Bernstein SE, etal. Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Behavioural and biological results. Arch Gen Psychiatry 1990; 47: 926-932.
153. Koran LM, Saxena S. Issues and strategies in treating refractory obsessive-compulsive disorder. CNS Spectr 2000; 5(6) (suppl 4): 24-31.
154. Zajecka JM, Fawcett J, Guy C. Coexisting major depression and obsessive-compulsive disorder treated with venlafaxine. J Clin Psychopharmacol 1990; 10(2): 152-3.
155. Ananth J, Burgoyne K, Smith M, Swartz R. Venlafaxine for treatment of obsessive-compulsive disorder. Am J Psychiatry 1995; 152(12): 1832.
156. Grossman R, Hollander E. Treatment of obsessive-compulsive disorder with venlafaxine. Am J Psychiatry 1996; 153(4): 576-7.
157. Yaryura-Tobias JA, Neziroglu FA. Venlafaxine in obsessive-compulsive disorder. Arch Gen Psychiatry 1996; 53(7): 653-654.
158. Tenney NH, Denys DA, van Megen HJ, Glas G, Westenberg HG. Effect of a pharmacological intervention on quality of life in patients with obsessive-compulsive disorder, Int Clin Psychopharmacol 2003; 18(1): 29-33.
159. Maina G, Albert U, Bogetto P. Venlafaxine in treatment resistant OCD patients: a single-blind, randomised, controlled study versus clomipramine and citalopram. Eur Neuropsychopharmacol 2001; 11(suppl 2): S66.
160. Koran, LM, Quirk T, Lorberbaum JP, Elliott M. Mirtazapine treatment of obsessive-compulsive disorder. J Clin Psychopharmacol 2001; 21(5): 537-9.
161. Koran LM, Gamel NN, Choung HW, Smith EH, Aboujaoude EN. Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation. J Clin Psychiatry 2005; 66(4): 515-20.
162. Insel TR, Murphy DL, Cohen RM, Alterman I, Kilts C, Linnoila M. Obsessive-compulsive disorder. A double-blind trial of clomipramine and clorgyline. Arch Gen Psychiatry 1983; 40(6): 605-12.
163. Vallejo J, Olivares J, Marcos T, Bulbena A, Menchon JM. Clomipramine versus phenelzine in obsessive-compulsive disorder. A controlled clinical trial. Br J Psychiatry 1992; 161: 665-70.
164. Jenike MA, Baer L, Munichiello WE, Rauch SL, Buttolph ML. Placebo-controlled trial of fluoxetine and phenelzine for obsessive-compulsive disorder. Am J Psychiatry 1997; 154(9): 1261-4.
165. Hewlett WA, Vinogradov S, Agras WS. Clomipramine, clonazepam and clonidine treatment of obsessive-compulsive disorder. J Clin Psychopharmacol 1992; 12(6): 420-30.
166. Hollander E, Kaplan A, Stahl SM. A double-blind, placebo-controlled trial of clonazepam in obsessive-compulsive disorder. World J Biol Psychiatry 2003; 4: 30-4.
167. Pato MT, Pigott TA, Hill JL, Grover GN, Bernstein S, Murphy DL. Controlled comparison of buspirone and clomipramine in obsessive-compulsive disorder. Am J Psychiatry 1991; 148(1): 127-9.
168. Fux M, Levine J, Aviv A, Belmaker RH. Inositol treatment of obsessive-compulsive disorder. Am J Psychiatry 1996; 153(9): 1219-21.
169. Lopes AC, de Mathis ME, Canteras MM, Salvajoli JV, Del Porto JA, Miguel EC. Update on neurosurgical treatment for obsessive compulsive disorder. Rev Bras Psiquiatr 2004; 26(1): 62-6.
170. Dell'Osso B, Altamura AC, Allen A, Hollander E. Brain stimulation techniques in the treatment of obsessive-compulsive disorder: current and future directions. CNS Spectr 2005; 10(12): 966-79, 983.
171. Khanna S, Gangadhar BN, Sinha V, Rajendra PN, Channabasavanna SM. Electroconvulsive therapy in obsessive-compulsive disorder. Convuls Ther 1988; 4: 314-320.
172. Soyka M, Niederecker M, Meyendorf R. Successful treatment of a therapy-refractory compulsive syndrome by electroconvulsive therapy. Nervenarzt 1991; 62: 448-50.
173. Husain MM, Lewis SF, Thornton WL. Maintenance ECT for refractory obsessive-compulsive disorder. Am J Psychiatry 1993; 150: 1899-1900.
174. Casey DA, Davis MH. Obsessive-compulsive disorder responsive to electroconvulsiye therapy in an elderly woman. South Med J 1994; 87(8): 862-4.
175. Wohlfahrt A. Electroconvulsive therapy in compulsive syndromes. A case report. Nervenarzt 1996; 67: 397-9.
176. Swartz CM, Shen WW. Is episodic obsessive compulsive disorder bipolar? A report of four cases. J Affect Disord 1999; 56(1): 61-6.
177. Fukuchi T, Okada Y, Katayama H, et al. A case of pregnant woman with severe obsessive-compulsive disorder successfully treated by modified-electroconvulsive therapy. Seishin Shinkeigaku Zasshi 2003; 105(7): 927-32.
178. Strassnig M, Riedel M, Müller N. Electroconvulsive therapy in a patient with Tourette's syndrome and co-morbid Obsessive Compulsive Disorder. World J Biol Psychiatry 2004; 5(3): 164-6.
179. Chaves MP, Crippa JA, Morais SL, Zuardi AW. Electroconvulsive therapy for coexistent schizophrenia and obsessive-compulsive disorder. J Clin Psychiatry 2005; 66: 542-3.
180. Maletzky B, McFrland B, Burt A. Refractory obsessive compulsive disorder and ECT. Convuls Ther 1994; 10: 34-42.
181. Sachdev PS, McBride R, Loo CK, Mitchell PB, Malhi GS, Croker VM. Right versus left prefrontal transcranial magnetic stimulation for obsessive-compulsive disorder: a preliminary investigation. J Clin Psychiatry 2001; 62: 981-4.
182. Mantovani A, Lisanby SH, Pieraccini F, Ulivelli M, Castrogiovanni P, Rossi S. Repetitive transcranial magnetic stimulation (rTMS) in the treatment of obsessive-compulsive disorder (OCD) and Tourette's syndrome (TS). Int J Neuropsychopharmacol 2006; 9: 95-100.
183. Alonso P, Pujol J, Cardoner N, et al. Right prefrontal repetitive transcranial magnetic stimulation in obsessive-compulsive disorder: a double-blind, placebo-controlled study. Am J Psychiatry 2001; 158: 1143-5.
184. Prasko J, Paskova B, Zalesky R, et al. The effect of repetitive transcranial magnetic stimulation (rTMS) on symptoms in obsessive compulsive disorder. A randomized, double-blind, sham controlled study. Neuro Endocrinol Lett 2006; 27: 327-32.
185. Sachdev PS, Lao CK, Mitchell PB, McFarquhar TF, Malhi GS. Repetitive transcranial magnetic stimulation for the treatment of obsessive compulsive disorder: a double-blind controlled investigation. Psychol Med 2007; 37(11): 1645-9.
186. Wichmann T, Delong MR. Deep brain stimulation for neurologic and neuropsychiatric disorders. Neuron 2006; 52: 197-204.
187. Lipsman N, Neimat JS, Lozano AM. Deep brain stimulation of for treatment-refractory obsessive-compulsive disorder: the search for a valid target. Neurosurgery 2007; 61(1): 1-11; discussion 11-3.
188. Anderson D, Ahmed A. Treatment of patients with intractable obsessive-compulsive disorder with anterior capsular stimulation. Case report. J Neurosurg 2003; 98: 1104-8.
189. Aouizerate B, Cuny B, Martin-Guehl C, et al. Deep brain stimulation of the ventral caudate nucleus in the treatment of obsessive-compulsive disorder and major depression. Case report. J Neurosurg 2004; 101: 682-6.
190. Fontaine D, Mattei V, Borg M, et al. Effect of subthalamic nucleus stimulation on obsessive-compulsive disorder in a patient with Parkinson disease. Case report. J Neurosurg 2004; 100: 1084-6.
191. Gabriels L, Cosyns P, Nuttin B, Demeulemeester H, Gybels J. Deep brain stimulation for treatment-refractory obsessive-compulsive disorder. Psychopathological and neuropsychological outcome in three cases. Acta Psychiatr Scand 2003; 107: 275-282.
192. Nuttin BJ, Gabriels LA, Cosyns PR, et al. Long-term electrical capsular stimulation in patients with obsessive-compulsive disorder. Neurosurgery 2003; 52: 1263-74.
193. Sturm V, Lenartz D, Koulousakis A, et al. The nucleus accumbens: A target for deep brain stimulation in obsessive-compulsive and anxiety disorders. J Chem Neuroanat 2003; 26: 293-9.
194. Abelson JL, Curtis GC, Sagher O, et al. Deep brain stimulation for refractory obsessive-compulsive disorder. Biol Psychiatry 2005; 57: 510-6.
195. Greenberg BD, Malone DA, Friehs GM, et al. Three-year outcomes in deep brain stimulation for highly resistant obsessive-compulsive disorder. Neuropsychopharmacology 2006; 31: 2384-93.
196. Lopes AC, de Mathis ME, Canteras MM, Salvajoli JV, Del Porto JA, Miguel EC. Update on neurosurgical treatment for obsessive-compulsive disorder. Rev Bras Psiquiatr 2004; 26: 62-6.
197. Jung HH, Kim CH, Chang JH, Park YG, Chung SS, Chang JW. Bilateral anterior cingulotomy for refractory obsessive-compulsive disorder: Long-term follow-up results. Stereotact Funct Neurosurg 2006; 84: 184-9.